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The concentration of oestrogen receptors (ER) in a
breast cancer is now well established as an index
for predicting the subsequent response of the
disease to endocrine therapy (Hawkins et al., 1980).
Oestrogen receptor concentration is influenced by
menstrual status, tumour cellularity and tumour
grade (Steele et al., 1982), and also rises with
increasing age (e.g., Clark & McGuire, 1983;
Mercer et al., 1983; Daxenbichler et al., 1982). The
influence of tissue and plasma levels of oestrogen
on ER concentration, however, is as yet less clearly
understood: whilst high levels of circulating
oestrogen have been found to be associated with
low/absent tumour ER in premenopausal women
(Maass et al., 1972; Nagai et al., 1979; Hawkins et
al., 1979), less is known about this relationship in
postmenopausal women.
In the present study, we have examined the
quantitative relationship between plasma oestrogens
and ER in the tumours from 50 postmenopausal
women.
Plasma for the assay of oestrone and oestradiol-
17/3 and tumour for the assay of ER were obtained
from 50 postmenopausal women with primary
cancer of the breast. Plasma samples were obtained
betweem 9 a.m. and 11 a.m. in the week prior to
operation, and at operation, the tumour was placed
on ice for immediate transfer to the laboratory.
Oestrogen receptor activity was determined by by
saturation analysis (Hawkins et al., 1975) with
minor modifications. A portion of tumour (300mg)
was homogenised (1:10w/v) in Tris buffer (10mM
Tris, 0.25 M sucrose, 1 mm ethylene diamine tetrace-
tate, containing 10% v/v glycerol and 1%
monothioglycerol) and centrifuged at 2040g for
20min. Aliquots of the resulting cytosol were in-
cubated overnight at 40C with 0.031 nM [2,3,6,7-3H]
oestradiol and varying amounts of competing
non-radioactive oestradiol (0, 0.03, 0.09, 0.15, 0.21,
0.28, 3.06 and 61.2nM). Free and bound steroid
B.J.C.-H
fractions were separated by the addition of dextran-
coated charcoal suspension, adsorption and centri-
fugation, and the radioactivity in the bound
fraction was determined by liquid scintillation
counting. The concentration of receptor was
calculated by 6-point Scatchard analysis (Scatchard,
1949). Cytosolic protein concentration was
determined by the method of Bradford (1976) and
receptor levels in excess of 5fmolmg-1 tumour
cytosol protein were regarded as positive.
Radioimmunoassay of plasma oestrone Plasma
samples (1 ml), diluted 1: 1 (v/v) with water plus
7.4fmol tracer [2,4,6,7-3H], oestrone, were extracted
with 10ml of Analar ether. The extract was
backwashed with 0.2ml of 8% (w/v) sodium
bicarbonate solution, evaporated to dryness and
dissolved in Tris buffer. A portion (1/3) was
removed and counted to assess manipulative losses
and the remainder was used for radioimmunoassay.
After overnight incubation at 4°C with 0.1ml of
antioestrone antibody (1:62,750 v/v in buffer), 0.1 ml
of [2,4,6,7-3H] oestrone solution ( 10,000cpm
was added). Bound hormone was separated from
free by the addition of dextran-coated charcoal
and adsorption: after centrifugation, the radioactivity
in the bound fraction was measured by liquid
scintillation counting. The amount of oestrone
present was determined by reference to a standard
curve derived from known amounts of radioinert
oestrone (0.003-0.617pmolml-') and was corrected
for manipulative losses. Values were expressed as
nmol oestronel- 1 plasma.
Radioimmunoassay of oestradiol-17# Similarly,
2ml samples of plasma, after the addition of 0.2ml
of 0.3M sodium hydroxide solution and 7.4fmol
[3H] oestradiol-17/3 tracer, were extracted with
ether. The extract was backwashed with 0.2ml of
water and the ether extract was evaporated to
dryness. After removal of a portion (1/3) for
counting to monitor losses, the remainder was
subjected to radioimmunoassay using an antibody
against oestradiol-17/ (1:83,000 v/v) and [3H]
oestradiol as radioligand. The mass of oestradiol-
17/ present was read from a standard curve
prepared using radioinert oestradiol-17/ and after
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correction for manipulative losses, the results were
expressed as nmol oestradioll1 plasma.
Of the 50 tumours investigated, 36 (72%) were
ER-positive and 14 (28%) ER-negative. The
concentrations of oestrone and oestradiol-17,B in the
plasmas from patients with ER-positive and -
negative tumours are shown in Figure 1. No
significant difference in plasma oestrogen
concentration was evident between these two
groups of tumours (P>0.l Wilcoxon Rank sum
test) for either oestrogen.
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Figure 2 The quantitative relationship between the
concentrations of oestrone in plasma and oestrogen
receptors in the tumour. By Spearman's rank
correlation test, r=0.50, P<0.01.
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Figure 1 Levels of plasma oestrogen in women with
ER-positive and negative tumours. Horizontal lines
indicate median values.
For the 36 ER-positive tissues, the quantitative
relationships between the concentration of ER in
the tumour and of those oestrone or oestradiol in
the plasma are shown in Figures 2 and 3. A
significant positive correlation was found between
the level of ER in the tumour and the level of
oestrone in the plasma (r=0.50, P<0.01,
Spearman's rank correlation test). There was also a
tendency for the levels of tumour ER to rise with
increasing plasma oestradiol concentration but this
did not attain significance (r=0.26, P>0.10,
Spearman's rank correlation test).
These results demonstrate that in postmenopausal
women, in contrast to our earlier findings in
premenopausal subjects (Hawkins et al., 1979), the
level of oestrogen receptor activity detected in a
breast cancer, which has prognostic and predictive
value, is correlated with the concentration of the
major circulating, unconjugated oestrogen,
oestrone. The plasma levels of oestradiol-17# were
much lower, and showed a similar, but non-
significant relationship with tumour ER activity.
Our findings are in agreement with those of Saez
and her colleagues (1978) who found that tumour
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Figure 3 The quantitative relationship between the
concentrations of oestradiol-17,B in the plasma and
oestrogen receptors in the tumour. By Spearman's rank
correlation test, r=0.26, P<0.10.
ER levels were significantly correlated with plasma
oestrogen level in a group of postmenopausal
patients with tumours positive for both oestrogen
and progestogen receptors. Drafta et al. (1983), on
the other hand, found that the plasma oestradiol
concentration was higher in patients with receptor-
positive tumours than in those with receptor-
negative tumours.
The present study implies that the levels of
circulating oestrogens, (- 0.02-0.08nmolI1- for
oestradiol, -0.04-0.20nmol 1 ' for oestrone) are
sufficient to half-saturate the oestrogen receptor
(- ~0.03nmol -' for oestradiol, -0.09nmoll-1 for
oestrone at 4°C) and may thus influence the rate of
its synthesis or degradation in the tumour.
However, it seems likely that it is the level of
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oestrogen in the tissue, rather than that in the
plasma which ultimately influences ER levels. In
tumour tissue, the endogenous oestrogens derive
not only from the plasma, but also from
biosynthesis within the tumour (Miller & Forrest,
1974; Miller et al., 1981; Mason et al., 1981) and
hydrolysis of oestrone sulphate (Santner et al.,
1984); oestradiol rather than oestrone appears to be
the major free oestrogen (Poortman et al., 1983). In
general, in tumour tissue, oestrogen concentrations
are likely to be higher when ER are present than
when they are absent (Fishman et al., 1977; Edery
et al., 1981; Thorson et al., 1982; Drafta et al.,
1983), and in one study (Edery et al., 1981), tumour
oestradiol content rose with increasing ER level.
Oestrogens can affect receptor levels in at least
two ways: (i) they fill empty receptor sites and (ii)
they may influence the rate of synthesis or
degradation of receptor (see e.g. Hawkins et al.,
1977; Bayard et al., 1978). This study suggests that
whilst the former effect may predominate in
premenopausal women, where progesterone levels
may determine oestrogen receptor synthesis (Saez et
al., 1978), the latter effect may occur, to some
extent, in postmenopausal subjects.
We thank Professor A.P.M. Forrest for his advice and
support during this study. R.C. Mason received full-time
financial support as an MRC Training Fellow.
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